Why was the weight -reducing medicine -revolution?

A new weight reduction category, known as the GLP-1, caused a fundamental shift in obesity treatments, and I estimated billions of dollars in the two pharmaceutical companies (Eli Lilly) and Novo Nordisk. However, the increasing demand for this US medicine has been accompanied by some challenges, including the reluctance of insurance companies to cover the costs of these treatments, which can amount to 16 thousand dollars annually. A short time ago, the shortage of obesity treatments led to the spread of cheaper alternatives produced by pharmacies, and the US Food and Drug Administration announced between 2024 and the beginning of 2025 that Elie Lily and Novo Nordsek were able to meet the demand, which threatened the noniginal alternative market. Another variable is the new US Minister of Health and Humanitarian Services, Robert Kennedy Junior, who has expressed reservations about the pharmaceutical sector in general, especially the new “magical” drug category. The “GLB -1” medicine is the two most important “GLB -1” medicine to treat obesity currently available on the market, “Wegozi” of “Novbound” by Elie Lily. Wigofi contains the same drug in Ozempic, approved by the US Food and Drug Administration for Diabetes, but with a slightly higher dose, while “Zepopond” contains the same drug in the diabetes medication “Montarua” of “Eli Lily”. The two companies have had trouble meeting the demand for the two medicines since they were erected a few years ago, but the problem of lack of supplies, according to the Food and Drug Administration, was largely solved. With the availability of the availability of original medicine, the cancellation of the food and drug administration can lead to the classification of these treatments as a shortage of supplies to reduce the availability of cheaper composite medicines, because this decision means that pharmacies that are medicines, a night “and” Novo medicine. Pharmaceutical products pharmacists responded by filling out a lawsuit against the food and drug administration, and on March 5, a federal judge issued a decision that forced the dwelminstallation companies to stop making copies of “Night” medicine. Based on this decision, the small pharmacies, which mainly depend on the installation of medicines for individuals, immediately cease to produce these medicines, while the largest pharmacies entrusted with production received a deadline to stop it until March 19. While the judiciary has not yet decided to provide copies of “Novo” medicine, he & Hers Hershels, which provides distance health services, announced on February 25 that he will stop producing a few copies of “Novo” drugs pending the coming ban. The future of the prices of “GLB -1” medicine If the pharmacies of the composition of the medicine cease to make this medicine, patients will lose the ability to obtain copies of obesity treatments at a cost of no more than $ 200 per month, or five the cost of the cost of the original medicine from the production of large brands, but in return, the complicated copies are subject to the same safety and strictly effective drugs. Elie Lily and Novo have announced plans to sell reduced copies of their directors directly to patients whose coverage does not include medicine for obesity treatment. On February 21, ‘Lily’ announced the price of “Zipond” packages with two doses $ 2.5, 5 mg with approximately $ 50 to $ 349 and $ 499 respectively. Patients whose coverage of insurance does not include medicine for weight loss, on a copy of the “Zibound” medicine found in colors, and is available at half the price of the medicine packed in injection pins, but this cheapest option requires users to fill the injection themselves when receiving the drug. On March 5, “Novo” announced that it would sell the bottled version of the “Wigofi” injection pens at a reduced $ 499 per month for patients who were not covered by health insurance, while the official price of “Wigofi” in the United States is approximately $ 1350 a month. What is the problem of insurance coverage? Many patients have lost their insurance coverage for this treatment, while others could not obtain this coverage from the ground because insurance companies refuse to pay the price of this high medicine, and therefore consumers were forced to pay their prices out of their pockets, or to be satisfied with buying the complicated medicine. According to the 2024 Mercyr’s “Mercer” polls of employers supported by employers, 44% of senior employers provide health coverage that includes weight reduction medicines, but almost most of them limit this coverage with those who meet very specific criteria. ‘Medicir’ – a health insurance program for Americans aged 65 and older – does not cover weight loss. The Joe Biden Administration has proposed a base that obliges the program to cover this medicine, but the final decision will be left to the Donald Trump administration to decide whether to acknowledge or reject this rule. Kennedy, whose ministry oversee the Food and Drug Administration, Medicir and Midikid service centers, said the first defense line to avoid obesity and other chronic illnesses is the lifestyle and a healthy diet, despite the importance of medicine. But on the other hand, Elon Musk, a consultant close to Trump, supported the availability of “GLB -1” medicine at very low prices for all, suggesting that he used these drugs personally. The most effective GLP-1 helps the remedy available in the market to reduce weight by simulating the “GLB-1” hormone secreted by the intestines after eating to achieve a sense of saturation. Zipondal is also aimed at another intestinal hormone known as GIP (GIP) that helps lower blood sugar levels and improve metabolism. The “Zepopond” medicine overwhelms “wigofi” in a clinical trial funded by “Eli Lily”, and the study included 751 patients with obesity, as the weights of patients who took “Zipond” fell by 20.2% within 72 weeks, and those who received “wijfi” reduced the percentage of their weights, according to the announcement in early December. Property offers additional benefits other than weight loss, as “wigofi” is the only medication of the “GLB-1” category, proven to be protected from heart attacks and other cardiovascular disease in people with heart disease and obesity, and in December “Zipond” became the first remedy to treat sleep apnea. Can future medicine be improved? Possible profits have attracted several pharmaceutical businesses after the race to develop weight loss treatments, while the two leading companies in this area, “Eli Lily” and “Novo”, are working on more effective treatments that exceed their current medicine before the patent expired. But it is not yet clear to what extent the effectiveness of the zipond can improve, if possible. “Novo” is testing a new drug from the next generation known as “Cagrism”, and the company officials have indicated that it can help more weight reduction compared to “zipopond”, where “cagersyme” the hormone “GLB1” and another boat with the name “cagerient tide” combine the hormone “. While old and new medicines are combating appetite, pharmaceutical businesses describe the effect of medicine that mimics the hormone “amilin” as the most kind of than those based on “GLB -1” because it helps their users to feel full for a longer period instead of eliminating their desire to eat completely. However, the first major study on “Cagersyma”, published in December, showed that the middle led to a weight loss by 20.4% within 68 weeks, which is an approach to the “Zipondal” percentage. The company is still testing the drug in other experiments, including a directly comparative study with “Zepopond”. Another promising medicine of the new generation is ‘Retatrutide’ by Elie Lily, which simulates three hormones: ‘GLB1’, ‘GIP’ and Tijlkagon, which helps regulate blood sugar levels. Experiments, with the expectation of the results in 2026. Later in the same year, experiences are taken on a boat twice a day due to its side effects. E Daily. Roche shares decreased in September after linking their experimental tablets in a preliminary study to serious side effects. Several other companies are still in the beginning stages of obesity tablets, including Merck, who obtained a license for an experimental remedy for obesity, were still in the pre -clinical trials in December. Thus, “Eli Lily” has one of the most powerful anti -obese tablets tested, as the drug “Orflipron” has reached the final stages of experiments, and its result is expected to be issued in 2025. The results of the interim increase that amounted to 14.7% in 36 a week. This content of “Eastern Economics with Bloomberg”